Pan Tumor Nivolumab Rollover Study - CA209-8TT
Updated: 27 September, 2019 | ClinicalTrials.gov
Print Friendly Summary
Inclusion Criteria: - - Signed Written Informed Consent - Participants who have completed treatment with nivolumab, progressed on prior nivolumab treatment or discontinued nivolumab due to toxicity in the Parent Protocol are not eligible to receive nivolumab in this study. These participants may be enrolled for safety and survival follow-up only. - Participant is eligible as per the Parent Protocol Exclusion Criteria: - - Participant ineligibility as per Parent Protocol.